# Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia

Study · id `cardio:ct-nct05365438` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05365438](<https://clinicaltrials.gov/study/NCT05365438>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05365438

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 105 participants.

## Technical summary

Registry record NCT05365438. Randomized; single masking; primary purpose treatment. Start 2022-10-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 105 participants (planned count; ClinicalTrials.gov record NCT05365438, source copy `cardio:ctgov-nct05365438-2026-05-05`, retrieved 2026-10-26)
- Started: 2022-10-01 (actual) (ClinicalTrials.gov record NCT05365438, source copy `cardio:ctgov-nct05365438-2026-05-05`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT05365438, source copy `cardio:ctgov-nct05365438-2026-05-05`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT05365438, source copy `cardio:ctgov-nct05365438-2026-05-05`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT05365438, source copy `cardio:ctgov-nct05365438-2026-05-05`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05365438-2026-05-05`, retrieved 2026-10-26)

## The registry's words

- Brief title: Atmeg (Atorvastatin and Omega-3 Combination) and Carotid Atherosclerosis in Patients With Type 2 Diabetes and Combined Dyslipidemia
- Condition: Dyslipidemias
- Condition: Atherosclerosis
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Omega 3-Atorvastatin
- Intervention (Drug): Omega 3-Atorvastatin
- Intervention (Drug): Atorvastatin-Ezetimibe
- Lead sponsor: Seoul National University Bundang Hospital
- Lead sponsor class: OTHER
- Collaborator: Korea United Pharm. Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Seoul National University Bundang Hospital (`cardio:org-seoul-national-university-bundang-hospital`)

## Provenance

Content hash: 0552d099ad76d64af92f16c81a210280a1ac627cd67e8240a8b6a645f6c15004
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
